Eric K. Chu

Emergency Medicine

6041 Cadillac Ave
Los Angeles, CA 90034

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Role of viral and host factors in determining the outcome of HBV-associated acute liver failure.

Role of viral and host factors in determining the outcome of HBV-associated acute liver failure.

Journal: Journal of translational medicine

Published: April 21, 2026

Time-Resolved Multi-Omics Identify Biomarkers of Immediate Reactions to mRNA Vaccination.

Time-Resolved Multi-Omics Identify Biomarkers of Immediate Reactions to mRNA Vaccination.

Journal: Allergy

Published: March 25, 2026

Evaluating Viral Load Sampling Schemes and Swabbing Methods for Optimal Surrogacy.

Evaluating Viral Load Sampling Schemes and Swabbing Methods for Optimal Surrogacy.

Journal: The Journal of infectious diseases

Published: August 20, 2025

Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.

Journal: Nature immunology

Published: July 14, 2025

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples.

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples.

Journal: The Journal of infectious diseases

Published: March 06, 2025

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood Samples.

A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure Proximal Design but Requires Far Fewer Blood Samples.

Journal: The Journal of infectious diseases

Published: March 06, 2025

The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death.

The Choice of Viral Load End Point in Early Phase Trials of COVID-19 Treatments Aiming to Reduce 28-Day Hospitalization and/or Death.

Journal: The Journal of infectious diseases

Published: January 19, 2025

Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine.

Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine.

Journal: The journal of allergy and clinical immunology. Global

Published: December 19, 2024

Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response.

Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response.

Journal: Nature communications

Published: December 05, 2024

Broadening diversity, equity, accessibility, and inclusion in the process and development of climate assessments.

Broadening diversity, equity, accessibility, and inclusion in the process and development of climate assessments.

Journal: Climatic change

Published: July 05, 2024

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.

Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.

Journal: Open forum infectious diseases

Published: June 20, 2024

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.

Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial.

Journal: Nature communications

Published: February 26, 2024

Showing 1-12 of 21

Last Updated: 09/26/2026